Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:736092.
doi: 10.1155/2015/736092. Epub 2015 May 7.

Nilotinib-Associated Destructive Thyroiditis

Suhalia Bakerywala  1 , Monica D Schwarcz  1 , Michael D Goldberg  1 , Guy Valiquette  1 , Irene A Weiss  1
Affiliations

Nilotinib-Associated Destructive Thyroiditis

Suhalia Bakerywala et al. Case Rep Endocrinol. 2015.

Abstract

Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia. Tyrosine kinases are enzymes expressed in multiple tissues and are involved in several signaling pathways influencing cellular growth. Below we describe a patient who developed an unusual complication of tyrosine kinase inhibitor therapy: thyrotoxicosis due to destructive thyroiditis. We review the pathophysiology of tyrosine kinase inhibitor-induced thyroid dysfunction particularly with regard to new second-generation tyrosine kinase inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Radioactive iodine uptake at 24 hours with very low uptake in thyroid bed.
See this image and copyright information in PMC

References

    1. Weisberg E., Manley P. W., Cowan-Jacob S. W., Hochhaus A., Griffin J. D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature Reviews Cancer. 2007;7(5):345–356. doi: 10.1038/nrc2126. - DOI - PubMed
    1. Illouz F., Laboureau-Soares S., Dubois S., Rohmer V., Rodien P. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. European Journal of Endocrinology. 2009;160(3):331–336. doi: 10.1530/eje-08-0648. - DOI - PubMed
    1. Makita N., Iiri T. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid. 2013;23(2):151–159. doi: 10.1089/thy.2012.0456. - DOI - PubMed
    1. Krause D. S., van Etten R. A. Tyrosine kinases as targets for cancer therapy. The New England Journal of Medicine. 2005;353(2):172–187. doi: 10.1056/nejmra044389. - DOI - PubMed
    1. Morabito A., de Maio E., Di Maio M., Normanno N., Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. The Oncologist. 2006;11(7):753–764. doi: 10.1634/theoncologist.11-7-753. - DOI - PubMed

LinkOut - more resources